#### Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

ACHILLIC Form 4 January 22,	ON PHARMACEU	JTICALS	INC						
FOR	<b>VI 4</b> this box nger to 16. or to tons ntinue. truction <b>STATEN</b> <b>STATEN</b> Filed pur Section 17(	<b>MENT OF</b> rsuant to S (a) of the I	Wa F CHAN Section Public U	ashington NGES IN SECUI 16(a) of th	, D.C. 20 BENEF RITIES ne Securi ding Con	<b>ICIAL O</b> ties Exchanger	E COMMISSION WNERSHIP OF ange Act of 1934, et of 1935 or Section 1940	OMB Number: Expires: Estimated burden hou response	urs per
1. Name and Address of Reporting Person <u>*</u> Barrish Joel C			2. Issuer Name <b>and</b> Ticker or Trading Symbol ACHILLION PHARMACEUTICALS INC [ACHN]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) C/O ACHI PHARMA GEORGE	ILLION CEUTICALS, IN	Middle) C., 300		of Earliest T Day/Year) 2016	ransaction		XOfficer (giv below) Chief	re title Oth below) Scientific Offic	
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tat	ole I - Non-l	Derivative	Securities	Acquired, Disposed o	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, -	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Reminder: Ro	eport on a separate line	e for each cla	ass of sec	eurities bene	Perso inforr requi	ns who re nation cor red to resp	or indirectly. espond to the collect ntained in this form bond unless the for ently valid OMB col	are not m	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option	\$ 7.61	01/20/2016		А	20,000	<u>(1)</u>	01/20/2026	Common Stock	20,000

#### Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Barrish Joel C C/O ACHILLION PHARMACEUTICALS, INC. 300 GEORGE STREET NEW HAVEN, CT 06511			Chief Scientific Officer		
Cinnetures					

### Signatures

/s/ Mary Kay Fenton, attorney-in-fact 01/22/2016

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the
   (1) original number of shares at the end of each successive three-month period following the first anniversary of the grant date until the fourth anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.